Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma
- PMID: 12700122
- DOI: 10.2741/865
Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma
Abstract
This article reviews studies on the correlation between genetic abnormalities in malignant astrocytic tumors and patient survival. It is almost certain that alterations of PTEN on chromosome 10 represent a significant unfavorable prognostic factor in glioblastoma patients. The association of alterations in p53, MDM2, p16 or EGFR with the survival of patients with anaplastic astrocytoma or glioblastoma remains controversial. It is possible that the p16 alteration and EGFR amplification are associated with poor survival in certain groups of patients and that there might be a relationship with age. Malignant transformation of astrocytic cells are driven by the sequential acquisition of genetic alteration. Therefore, it is reasonable to subgroup gliomas by their patterns of genetic alterations. However the studies that correlated the multiple genetic alterations with survival are still limited. Further studies on large cohorts are necessary to elucidate the genetic factors that affect the prognosis and response to therapy of patients with malignant gliomas and to develop effective management strategies.
Similar articles
-
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme.J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56. doi: 10.1093/jnci/93.16.1246. J Natl Cancer Inst. 2001. PMID: 11504770
-
Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.Neuro Oncol. 1999 Apr;1(2):124-37. doi: 10.1093/neuonc/1.2.124. Neuro Oncol. 1999. PMID: 11550308 Free PMC article. Review.
-
Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.Brain Pathol. 2000 Apr;10(2):249-59. doi: 10.1111/j.1750-3639.2000.tb00258.x. Brain Pathol. 2000. PMID: 10764044 Free PMC article.
-
Molecular genetic analysis of non-astrocytic gliomas.Histopathology. 1999 Apr;34(4):331-41. doi: 10.1046/j.1365-2559.1999.00603.x. Histopathology. 1999. PMID: 10231401
-
[Genes implicated in glial tumors].Morphologie. 2000 Jun;84(265):51-5. Morphologie. 2000. PMID: 11048299 Review. French.
Cited by
-
Genomic alterations in low-grade, anaplastic astrocytomas and glioblastomas.Pathol Oncol Res. 2007;13(1):39-46. doi: 10.1007/BF02893439. Epub 2007 Mar 27. Pathol Oncol Res. 2007. PMID: 17387387
-
Network analysis of microRNAs, transcription factors, target genes and host genes in human anaplastic astrocytoma.Exp Ther Med. 2016 Jul;12(1):437-444. doi: 10.3892/etm.2016.3272. Epub 2016 Apr 20. Exp Ther Med. 2016. PMID: 27347075 Free PMC article.
-
Logarithmic decrease of serum alpha-fetoprotein or human chorionic gonadotropin in response to chemotherapy can distinguish a subgroup with better prognosis among highly malignant intracranial non-germinomatous germ cell tumors.J Neurooncol. 2011 Sep;104(3):779-87. doi: 10.1007/s11060-011-0544-2. Epub 2011 Feb 26. J Neurooncol. 2011. PMID: 21359564
-
Expression Analysis of Genes Involved in the RB/E2F Pathway in Astrocytic Tumors.PLoS One. 2015 Aug 28;10(8):e0137259. doi: 10.1371/journal.pone.0137259. eCollection 2015. PLoS One. 2015. PMID: 26317630 Free PMC article.
-
Antioxidant Senotherapy by Natural Compounds: A Beneficial Partner in Cancer Treatment.Antioxidants (Basel). 2025 Feb 10;14(2):199. doi: 10.3390/antiox14020199. Antioxidants (Basel). 2025. PMID: 40002385 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous